Quantifying maternally derived respiratory syncytial virus specific neutralising antibodies in a birth cohort from coastal Kenya

Vaccine

Volumn 33, Issue 15, 2015, Pages 1797-1801

  Nyiro, Joyce U ^a   Sande, Charles ^a   Mutunga, Martin ^a   Kiyuka, Patience K ^a   Munywoki, Patrick K ^a   Scott, J Anthony G ^a,b   Nokes, D James ^a,c  

^a KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Birth cohort; Maternal antibody; Neutralisation; Rate of decay; Respiratory syncytial virus; Vaccine design

Indexed keywords

MATERNAL ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ANTIBODY TITER; ARTICLE; BIRTH; BLOOD SAMPLING; COHORT ANALYSIS; FOLLOW UP; GEOMETRY; GESTATION PERIOD; HALF LIFE TIME; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; INFANT; KENYA; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; VIRUS TRANSMISSION; BLOOD; EPIDEMIOLOGY; FEMALE; FETUS BLOOD; IMMUNOLOGY; SEASON; SERODIAGNOSIS; TIME FACTOR;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; COHORT STUDIES; FEMALE; FETAL BLOOD; HALF-LIFE; HUMANS; IMMUNITY, MATERNALLY-ACQUIRED; INFANT; KENYA; NEUTRALIZATION TESTS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; SEASONS; TIME FACTORS;

EID: 84925302154     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.02.039     Document Type: Article

References (22)

1. Nokes D.J., Ngama M., Bett A., et al. Incidence and severity of respiratory syncytial virus pneumonia in rural Kenyan children identified through hospital surveillance. Clin Infect Dis 2009, 49:1341-1349.
2. Nair H., Simoes E.A., Rudan I., et al. Global and regional burden of hospital admissions for severe acute lower respiratory infections in young children in 2010: a systematic analysis. Lancet 2013, 381:1380-1390.
3. Berkley J.A., Munywoki P., Ngama M., et al. Viral etiology of severe pneumonia among Kenyan infants and children. JAMA 2010, 303:2051-2057.
4. Graham B.S. Protecting the family to protect the child: vaccination strategy guided by RSV transmission dynamics. J Infect Dis 2014, 209:1679-1681.
5. Roca A., Abacassamo F., Loscertales M.P., et al. Prevalence of respiratory syncytial virus IgG antibodies in infants living in a rural area of Mozambique. J Med Virol 2002, 67:616-623.
6. Englund J., Glezen W.P., Piedra P.A. Maternal immunization against viral disease. Vaccine 1998, 16:1456-1463.
7. Glezen W.P., Paredes A., Allison J.E., et al. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr 1981, 98:708-715.
8. Lamprecht C.L., Krause H.E., Mufson M.A. Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus. J Infect Dis 1976, 134:211-217.
9. The Impact-RSV Study Group Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998, 102:531-537.
10. Piedra P.A., Jewell A.M., Cron S.G., et al. Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine 2003, 21:3479-3482.
11. Scott J.A., Bauni E., Moisi J.C., et al. Profile: the Kilifi Health and Demographic Surveillance System (KHDSS). Int J Epidemiol 2012, 41:650-657.
12. Nokes D.J., Okiro E.A., Ngama M., et al. Respiratory syncytial virus epidemiology in a birth cohort from Kilifi district, Kenya: infection during the first year of life. J Infect Dis 2004, 190:1828-1832.
13. English M., Muhoro A., Aluda M., et al. Outcome of delivery and cause-specific mortality and severe morbidity in early infancy: a Kenyan district hospital birth cohort. Am J Trop Med Hyg 2003, 69:228-232.
14. Nokes D.J., Okiro E.A., Ngama M., et al. Respiratory syncytial virus infection and disease in infants and young children observed from birth in Kilifi district, Kenya. Clin Infect Dis 2008, 46:50-57.
15. Sande C.J., Mutunga M.N., Okiro E.A., et al. Kinetics of the neutralizing antibody response to respiratory syncytial virus infections in a birth cohort. J Med Virol 2013, 85:2020-2025.
16. Sande C.J., Mutunga M.N., Medley G.F., et al. Group- and genotype-specific neutralizing antibody responses against respiratory syncytial virus in infants and young children with severe pneumonia. J Infect Dis 2013, 207:489-492.
17. Brandenburg A.H., Groen J., van Steensel-Moll H.A., et al. Respiratory syncytial virus specific serum antibodies in infants under six months of age: limited serological response upon infection. J Med Virol 1997, 52:97-104.
18. Glenn G.M., Smith G., Fries L., et al. Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine. Vaccine 2013, 31:524-532.
19. Chu H.Y., Steinhoff M.C., Magaret A., et al. Respiratory syncytial virus transplacental antibody transfer and kinetics in mother-infant pairs in Bangladesh. J Infect Dis 2014, 210:1582-1589.
20. Stensballe L.G., Ravn H., Kristensen K., et al. Seasonal variation of maternally derived respiratory syncytial virus antibodies and association with infant hospitalizations for respiratory syncytial virus. J Pediatr 2009, 154:296-298.
21. Suara R., Piedra P., Glezen W., et al. Prevalence of neutralizing antibody to respiratory syncytial virus in sera from mothers and newborns residing in the Gambia and in the United States. Clin Diagn Lab Immunol 1996, 3:477-479.
22. Englund J., Glezen W.P., Piedra P.A. Maternal immunization against viral disease. Vaccine 1998, 16:1456-1463.